It is the year $2025 .$ You are taking care of a patient who is concerned about having an early stage of kidney cancer. His mother died from this disease.
a. Assume that the SNPs linked to genes involved in the development of this type of cancer have been identified. How would you determine if this man has a genetic predisposition for developing kidney cancer? Explain how you would do the analysis.
b. How might you develop a metabolomic profile for kidney cancer and then use it to determine whether your patient has kidney cancer?
c. If the patient was diagnosed with cancer by the methods in (a) and (b), how would you use pharmacogenomics to choose the right medications to treat the tumor in this patient?